Ownership and insider activity for Oculis Holding AG (OCS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema.
Price
| Price | $9.97 |
| Market Cap | $570M |
| Exchange | NASDAQ |
| Country | CH |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $46.3M | $19.8M | $38.3M | $27.7M | $81.4M |
| Short-term Investments | 0 | 0 | 0 | $53.3M | $71.0M | $131.8M |
| Receivables | $1.1M | 0 | 0 | $8.0M | $777000 | $994127 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $6.2M | $48.0M | $23.7M | $101.0M | $104.9M | $219.1M |
| Property, Plant & Equipment | $1.4M | $1.3M | $1.1M | $1.0M | $1.7M | $3.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $8.7M | $8.7M | $12.2M | $12.2M | $13.3M | $13.3M |
| Total Assets | $16.4M | $58.0M | $37.1M | $114.4M | $120.4M | $236.2M |
| Accounts Payable | $790000 | $824000 | $3.9M | $7.6M | $5.9M | $1.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $502569 |
| Total Current Liabilities | $4.3M | $4.1M | $12.0M | $19.1M | $44.2M | $36.8M |
| Long-term Debt | $54.0M | $113.5M | $122.4M | 0 | 0 | 0 |
| Total Liabilities | $60.0M | $119.0M | $135.1M | $20.6M | $47.0M | $39.9M |
| Retained Earnings | -$53.7M | -$72.3M | -$111.0M | -$199.8M | -$285.6M | -$385.0M |
| Total Equity | -$43.7M | -$61.0M | -$98.0M | $93.7M | $73.4M | $196.3M |
| Total Debt | $54.8M | $114.3M | $123.1M | $605000 | $1.2M | $2.3M |
| Net Debt | $49.9M | $68.0M | $103.3M | -$91.0M | -$97.5M | -$210.9M |
| Working Capital | $1.8M | $43.9M | $11.6M | $81.9M | $60.7M | $182.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 8.35 |
Profitability
| Return on Equity | -42.92% |
| Return on Invested Capital | -38.94% |
| Return on Assets | -31.82% |
| Gross Margin | 35.21% |
| Operating Margin | -35874.24% |
| Net Margin | -32780.20% |
Related companies: ANAB · BBOT · KOD · MNMD · NKTR · NRIX · PHAT
Explore sector: Healthcare · Biotechnology
More sections of OCS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks